unknown
Open source record Compound Directory
BPC-157 + TB-500
A reviewed compound profile linking technical facts, evidence summaries, limitations, studies, trials, COAs, and related products.
Evidence limitations
Research evidence must match BPC-157, TB-500, or an explicitly identified component. Supplier/SKU codes are not accepted as evidence identities.
Reviewed sources
Clickable primary records and approved journal metadata.
unknown
Open source record pubmed
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Nikhil Vasireddi, Henrik Hahamyan, Michael J Salata, Michael Karns, Jacob G Calcei, James E Voos, John M Apostolakos · HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026
Systematic review or meta-analysis · Human participants; verify the population in the source
Open source recordpubmed
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.
Sven Seiwerth, Rudolf Rucman, Branko Turkovic, Marko Sever, Robert Klicek, Bozo Radic, Domagoj Drmic, Mirjana Stupnisek, Marija Misic, Lovorka Batelja Vuletic, Katarina Horvat Pavlov, Ivan Barisic, Antonio Kokot, Mladen Japjec, Alenka Boban Blagaic, Ante Tvrdeic, Dinko Stancic Rokotov, Hrvoje Vrcic, Mario Staresinic, Bozidar Sebecic, Predrag Sikiric · Current pharmaceutical design · 2019
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Daniel Gwyer, Nicholas M Wragg, Samantha L Wilson · Cell and tissue research · 2019
Preclinical animal study · Animal model; verify the species in the source
Open source recordpubmed
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
Michalina Józwiak, Marta Bauer, Wojciech Kamysz, Patrycja Kleczkowska · Pharmaceuticals (Basel, Switzerland) · 2025
Preclinical animal study · Animal model; verify the species in the source
Open source recordVerified COA records
Only approved public COAs matched to this product, strength, lot, and batch are shown.
current · Lot 062226
BPC157/TB500 (Wolverine)
Freedom Diagnostics (FreedomDiagnosticsTesting.com) · 2606220392 · 2026-06-22
historical · Lot FH-BB20-01
BPC157/TB500 (Wolverine)
ILS Laboratories LLC · 2026-08-03
Registered trials
NCT07437547 · RECRUITING
BPC 157 for Acute Hamstring Muscle Strain Repair
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
Outcomes: Time to return to unrestricted sport participation (days) · Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review. · Change in pain during activity on a 0-10 Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain). · Hamstring strength limb symmetry index (LSI) by isokinetic dynamometry · Change in Lower Extremity Functional Scale (LEFS; 0-80, higher scores indicate better function)
PHASE2
NCT07752381 · COMPLETED
A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery
This study will evaluate the effects of Parlay Recover peptide gummies (containing Body Protection Compound BPC-157) on markers of inflammation, physical performance, and recovery in physically active adults. Over an 8-week period, 40 participants will consume two gummies daily and complete questionnaires at Baseline, Week 2, Week 4, Week 6, and Week 8, as well as undergo blood testing at Baseline and Week 8. The primary objective is to examine changes in inflammatory biomarkers (hs-CRP and IL-6) as measured by blood testing. Secondary objectives include evaluating participants' self-reported perceptions of the product's effects on physical performance and recovery, including aching, stiffness, function, and recovery of muscles and joints.
Outcomes: Change in High-Sensitivity C-Reactive Protein (hs-CRP) · Change in Interleukin-6 (IL-6) · Change in Self-Reported Swelling · Change in Self-Reported Aching · Change in Self-Reported Stiffness · Change in Self-Reported Muscle Function · Change in Self-Reported Recovery
NA
NCT02637284 · UNKNOWN
PCO-02 - Safety and Pharmacokinetics Trial
Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source.
Outcomes: Adverse events · Maximum plasma concentration · Time to maximum plasma concentration · Area under the curve · Elimination half life
PHASE1